Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 17

Explainer

Peptides after surgery: the evidence

BPC-157, GHK-Cu and KPV get discussed as post-surgical recovery aids. No human trial has measured what any of them does to a healing surgical wound.

23 Jul 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

BPC-157, GHK-Cu and KPV after surgery

What the animal literature says about BPC-157, GHK-Cu, and KPV and post-surgical healing, and why the human evidence to guide restart timing does not yet exist.

23 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

PT-141 in women: onset and side effects

The RECONNECT Phase 3 trials enrolled 1,247 premenopausal women and documented onset timing, nausea rates, and the cardiovascular signal for bremelanotide.

23 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Retatrutide's overstimulated side effects

Forum users describe a wired, foggy feeling on retatrutide. Here is what the phase 2 trials recorded, and the large gap between that and anecdote.

23 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Retatrutide: the overstimulated side effect

Some retatrutide users report a wired, restless feeling during titration. The cause traces to GLP-1 receptor agonism activating brain sympathetic pathways.

23 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semax with armodafinil and nicotine

No published study has examined Semax alongside armodafinil or nicotine. Here is what the mechanisms suggest, and why silence is not a safety finding.

23 Jul 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Semax and armodafinil: dopamine overlap

No interaction study covers semax, armodafinil and nicotine together. Here is what the pharmacology shows about dopaminergic overlap.

23 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Thymosin β4 and pyroptosis in microglia

A July 2026 cell-culture study reports that thymosin beta-4 lowers pyroptosis markers in BV2 microglia. Here is what that does and does not show.

23 Jul 2026 · PeptideMethods Editorial Team · 5 min read
Country deep-dive

Tirzepatide in Sweden: import rules

In Sweden, tirzepatide (Mounjaro) is prescription-only and EU-authorised. Importing from outside the EEA requires dispensation and risks customs seizure.

23 Jul 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

Tirzepatide in Sweden: licence and cost

Mounjaro (tirzepatide) is licensed and prescribable in Sweden but sits outside the high-cost protection scheme. Here is what changed and what patients pay.

23 Jul 2026 · PeptideMethods Editorial Team · 6 min read
Explainer

BPC-157 and TB-500 for back pain

BPC-157 and TB-500 show tissue-repair effects in animal models, but no human trial has tested either for chronic back pain.

22 Jul 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

BPC-157 and TB-4 blend: reconstitution math

How to reconstitute a BPC-157 and TB-4 lyophilised blend, what the arithmetic actually means, and why no validated human dose exists for either peptide.

22 Jul 2026 · PeptideMethods Editorial Team · 4 min read